Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, has appointed Larry Good as chief medical officer.
According to the company, Dr Good's experience as a practicing gastroenterologist has strengthened the company's mission to develop novel treatments for lactose intolerance and other gastrointestinal disorders.
"Dr Good's appointment to the lead R&D role at Ritter acknowledges his contributions to our R&D team to date, and will provide valuable expertise as we advance our clinical programs," said Andrew Ritter, president and CEO of Ritter Pharmaceuticals.
"Ritter's approach to treating lactose intolerance and other GI disorders through colonic adaptation has the potential to change how these disorders are treated in the future," said Dr Good. "I look forward to overseeing future R&D at Ritter, including advanced clinical study design and implementation," he added.
Dr Good is a Fellow of the American College of Gastroenterology and has served as the Chief Physician in Gastroenterology at South Nassau Communities Hospital and Lydia E. Hall Hospital in New York. He joined Ritter Pharmaceuticals in 2012. Dr Good has conducted clinical research in a range of GI specialties, including biliary lipid metabolism, irritable bowel syndrome and inflammatory bowel disease.